FAS

(redirected from CD95)
Also found in: Dictionary, Medical, Financial, Encyclopedia, Wikipedia.
Related to CD95: Fas protein, Fas ligand
  • noun

Synonyms for FAS

a congenital medical condition in which body deformation occurs or facial development or mental ability is impaired because the mother drinks alcohol during pregnancy

Related Words

References in periodicals archive ?
Under normal circumstances, when the death receptor called CD95 is activated by specific proteins, the process of apoptosis is triggered.
Apocept (APG101) is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc portion of an IgG antibody.
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children.
The company's lead product candidate, Apocept (TM), a first-in-class, fully human fusion protein combining the extracellular domain of the CD95 receptor and the Fc portion of IgG, successfully completed a Phase I study in 2009.
Viard I, Wehrli P, Bullani R et al: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.
Application of CD95 ligand rendered E7 immortalized cells to extensive apoptosis while E6 and E6/E7 expressing keratinocytes were resistant (28).
Pierre Wallemacq: The list below is not exhaustive but just suggests some potential candidates from the current literature, including soluble and intracellular interleukins and antigens: (a) lymphocyte proliferation (PCNA); (b) expression of surface antigens of T cells (flow cytometry) (CD3, CD4, CD8, CD25, CD28, CD38, CD69, CD95, CD154); (c) IFN-[gamma] ELISPOT assay; (d) quantification of intracellular interleukin-2 (IL-2) in [CD8.
Involvement of the CD95 (APO-1/FAZ) receptor/ligand system in drug-induced apoptosis in leukemia cells.
Consistent with this hypothesis, tumor cell CD95 expression was reduced in the TS/A relative to the TS/A-AS (p=0.
The company's lead product candidate, APG101, a first-in-class, fully human fusion protein combining the extracellular domain of the CD95 receptor and the Fc portion of IgG, successfully completed a phase I study in 2009.
Fas, also known as CD95, is a type of receptor found on hepatocytes and is similar to one of the receptors for the cytokine TNF-[alpha] (also discussed in the next section).
Glioblastoma patients with a certain biomarker associated with the CD95 ligand experienced the greatest benefit from treatment with APG101.